INmune Bio (INMB)
(Delayed Data from NSDQ)
$10.84 USD
+0.22 (2.07%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $10.90 +0.06 (0.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INMB 10.84 +0.22(2.07%)
Will INMB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INMB
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
INMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Other News for INMB
Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio to sell 986,000 shares at $9.84 in registered direct offering
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
INmune Bio announces 24-month stability validation of XPro